To address the miR-635/RUNX2 axis, we additionally compared the expression of RUNX2, in the presence of wild-type or mutant TP53, in the HPV- (Supplementary Fig. S8A, left) and HPV+ (Supplementary Fig. S8B, left) HNSCC groups. This evidence concerns the gene RUNX2 and head and neck squamous cell carcinoma.